FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2224137722> ?p ?o ?g. }

• W2224137722 endingPage "1060" @default.
• W2224137722 startingPage "1052" @default.
• W2224137722 abstract "Purpose/Objective(s) To quantify ensuing bone marrow (BM) suppression during postoperative chemotherapy resulting from preoperative chemoradiation (CRT) therapy for rectal cancer. Methods and Materials We retrospectively evaluated 35 patients treated with preoperative CRT followed by postoperative 5-Fluorouracil and oxaliplatin (OxF) chemotherapy for locally advanced rectal cancer. The pelvic bone marrow (PBM) was divided into ilium (IBM), lower pelvis (LPBM), and lumbosacrum (LSBM). Dose volume histograms (DVH) measured the mean doses and percentage of BM volume receiving between 5-40 Gy (i.e.: PBM-V5, LPBM-V5). The Wilcoxon signed rank tests evaluated the differences in absolute hematologic nadirs during neoadjuvant vs. adjuvant treatment. Logistic regressions evaluated the association between dosimetric parameters and ≥ grade 3 hematologic toxicity (HT3) and hematologic event (HE) defined as ≥ grade 2 HT and a dose reduction in OxF. Receiver Operator Characteristic (ROC) curves were constructed to determine optimal threshold values leading to HT3. Results During OxF chemotherapy, 40.0% (n=14) and 48% (n=17) of rectal cancer patients experienced HT3 and HE, respectively. On multivariable logistic regression, increasing pelvic mean dose (PMD) and lower pelvis mean dose (LPMD) along with increasing PBM-V (25-40), LPBM-V25, and LPBM-V40 were significantly associated with HT3 and/or HE during postoperative chemotherapy. Exceeding ≥36.6 Gy to the PMD and ≥32.6 Gy to the LPMD strongly correlated with causing HT3 during postoperative chemotherapy. Conclusions Neoadjuvant RT for rectal cancer has lasting effects on the pelvic BM, which are demonstrable during adjuvant OxF. Sparing of the BM during preoperative CRT can aid in reducing significant hematologic adverse events and aid in tolerance of postoperative chemotherapy. To quantify ensuing bone marrow (BM) suppression during postoperative chemotherapy resulting from preoperative chemoradiation (CRT) therapy for rectal cancer. We retrospectively evaluated 35 patients treated with preoperative CRT followed by postoperative 5-Fluorouracil and oxaliplatin (OxF) chemotherapy for locally advanced rectal cancer. The pelvic bone marrow (PBM) was divided into ilium (IBM), lower pelvis (LPBM), and lumbosacrum (LSBM). Dose volume histograms (DVH) measured the mean doses and percentage of BM volume receiving between 5-40 Gy (i.e.: PBM-V5, LPBM-V5). The Wilcoxon signed rank tests evaluated the differences in absolute hematologic nadirs during neoadjuvant vs. adjuvant treatment. Logistic regressions evaluated the association between dosimetric parameters and ≥ grade 3 hematologic toxicity (HT3) and hematologic event (HE) defined as ≥ grade 2 HT and a dose reduction in OxF. Receiver Operator Characteristic (ROC) curves were constructed to determine optimal threshold values leading to HT3. During OxF chemotherapy, 40.0% (n=14) and 48% (n=17) of rectal cancer patients experienced HT3 and HE, respectively. On multivariable logistic regression, increasing pelvic mean dose (PMD) and lower pelvis mean dose (LPMD) along with increasing PBM-V (25-40), LPBM-V25, and LPBM-V40 were significantly associated with HT3 and/or HE during postoperative chemotherapy. Exceeding ≥36.6 Gy to the PMD and ≥32.6 Gy to the LPMD strongly correlated with causing HT3 during postoperative chemotherapy. Neoadjuvant RT for rectal cancer has lasting effects on the pelvic BM, which are demonstrable during adjuvant OxF. Sparing of the BM during preoperative CRT can aid in reducing significant hematologic adverse events and aid in tolerance of postoperative chemotherapy." @default.
• W2224137722 created "2016-06-24" @default.
• W2224137722 creator A5019969198 @default.
• W2224137722 creator A5031621111 @default.
• W2224137722 creator A5031744913 @default.
• W2224137722 creator A5031778112 @default.
• W2224137722 creator A5034704814 @default.
• W2224137722 creator A5069565044 @default.
• W2224137722 creator A5077716269 @default.
• W2224137722 creator A5090216308 @default.
• W2224137722 date "2016-04-01" @default.
• W2224137722 modified "2023-10-17" @default.
• W2224137722 title "Long-Term Bone Marrow Suppression During Postoperative Chemotherapy in Rectal Cancer Patients After Preoperative Chemoradiation Therapy" @default.
• W2224137722 cites W1631147138 @default.
• W2224137722 cites W17456534 @default.
• W2224137722 cites W1944391634 @default.
• W2224137722 cites W1965854742 @default.
• W2224137722 cites W1965877617 @default.
• W2224137722 cites W1966064650 @default.
• W2224137722 cites W1966853096 @default.
• W2224137722 cites W2002225209 @default.
• W2224137722 cites W2006617902 @default.
• W2224137722 cites W2022942708 @default.
• W2224137722 cites W2045804591 @default.
• W2224137722 cites W2047348005 @default.
• W2224137722 cites W2065493387 @default.
• W2224137722 cites W2066077329 @default.
• W2224137722 cites W2076341925 @default.
• W2224137722 cites W2082603775 @default.
• W2224137722 cites W2085986655 @default.
• W2224137722 cites W2092767351 @default.
• W2224137722 cites W2094087519 @default.
• W2224137722 cites W2095326439 @default.
• W2224137722 cites W2097656606 @default.
• W2224137722 cites W2116017558 @default.
• W2224137722 cites W2124297369 @default.
• W2224137722 cites W2125452425 @default.
• W2224137722 cites W2138985803 @default.
• W2224137722 cites W2143743735 @default.
• W2224137722 cites W2152511454 @default.
• W2224137722 cites W2157091913 @default.
• W2224137722 cites W2164891366 @default.
• W2224137722 cites W2170552969 @default.
• W2224137722 cites W2212807488 @default.
• W2224137722 cites W2323577539 @default.
• W2224137722 cites W2335261075 @default.
• W2224137722 doi "https://doi.org/10.1016/j.ijrobp.2015.12.374" @default.
• W2224137722 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27026312" @default.
• W2224137722 hasPublicationYear "2016" @default.
• W2224137722 type Work @default.
• W2224137722 sameAs 2224137722 @default.
• W2224137722 citedByCount "26" @default.
• W2224137722 countsByYear W22241377222017 @default.
• W2224137722 countsByYear W22241377222018 @default.
• W2224137722 countsByYear W22241377222019 @default.
• W2224137722 countsByYear W22241377222020 @default.
• W2224137722 countsByYear W22241377222021 @default.
• W2224137722 countsByYear W22241377222022 @default.
• W2224137722 countsByYear W22241377222023 @default.
• W2224137722 crossrefType "journal-article" @default.
• W2224137722 hasAuthorship W2224137722A5019969198 @default.
• W2224137722 hasAuthorship W2224137722A5031621111 @default.
• W2224137722 hasAuthorship W2224137722A5031744913 @default.
• W2224137722 hasAuthorship W2224137722A5031778112 @default.
• W2224137722 hasAuthorship W2224137722A5034704814 @default.
• W2224137722 hasAuthorship W2224137722A5069565044 @default.
• W2224137722 hasAuthorship W2224137722A5077716269 @default.
• W2224137722 hasAuthorship W2224137722A5090216308 @default.
• W2224137722 hasConcept C121608353 @default.
• W2224137722 hasConcept C126322002 @default.
• W2224137722 hasConcept C126894567 @default.
• W2224137722 hasConcept C141071460 @default.
• W2224137722 hasConcept C143998085 @default.
• W2224137722 hasConcept C2776581026 @default.
• W2224137722 hasConcept C2776694085 @default.
• W2224137722 hasConcept C2778424827 @default.
• W2224137722 hasConcept C526805850 @default.
• W2224137722 hasConcept C71924100 @default.
• W2224137722 hasConceptScore W2224137722C121608353 @default.
• W2224137722 hasConceptScore W2224137722C126322002 @default.
• W2224137722 hasConceptScore W2224137722C126894567 @default.
• W2224137722 hasConceptScore W2224137722C141071460 @default.
• W2224137722 hasConceptScore W2224137722C143998085 @default.
• W2224137722 hasConceptScore W2224137722C2776581026 @default.
• W2224137722 hasConceptScore W2224137722C2776694085 @default.
• W2224137722 hasConceptScore W2224137722C2778424827 @default.
• W2224137722 hasConceptScore W2224137722C526805850 @default.
• W2224137722 hasConceptScore W2224137722C71924100 @default.
• W2224137722 hasIssue "5" @default.
• W2224137722 hasLocation W22241377221 @default.
• W2224137722 hasLocation W22241377222 @default.
• W2224137722 hasOpenAccess W2224137722 @default.
• W2224137722 hasPrimaryLocation W22241377221 @default.
• W2224137722 hasRelatedWork W2347272611 @default.
• W2224137722 hasRelatedWork W2347397395 @default.
• W2224137722 hasRelatedWork W2351170859 @default.
• W2224137722 hasRelatedWork W2360584503 @default.
• W2224137722 hasRelatedWork W2372808635 @default.

• next